PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 85 filers reported holding PHATHOM PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,445,039 | +261.2% | 139,348 | +398.7% | 0.00% | – |
| Q2 2023 | $400,115 | +96780.1% | 27,941 | -51.7% | 0.00% | – |
| Q1 2023 | $413 | -99.9% | 57,863 | +14.8% | 0.00% | – |
| Q3 2022 | $558,000 | +22.9% | 50,396 | +316.8% | 0.00% | – |
| Q1 2021 | $454,000 | -81.4% | 12,090 | -83.5% | 0.00% | -100.0% |
| Q4 2020 | $2,438,000 | – | 73,377 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 2,067,861 | $77,669,000 | 45.24% |
| FRAZIER MANAGEMENT LLC | 5,827,415 | $218,878,000 | 17.56% |
| Abingworth LLP | 1,203,135 | $45,057,000 | 15.56% |
| Greenspring Associates, LLC | 360,939 | $13,557,000 | 10.78% |
| Penn Mutual Asset Management, LLC | 86,940 | $3,265,000 | 3.69% |
| RA Capital Management | 3,115,008 | $117,000,000 | 1.76% |
| Rhenman & Partners Asset Management AB | 175,000 | $6,573,000 | 0.46% |
| Summit Rock Advisors, LP | 34,100 | $1,281,000 | 0.44% |
| Eventide Asset Management | 600,000 | $22,536,000 | 0.33% |
| Parkman Healthcare Partners LLC | 30,207 | $1,135,000 | 0.26% |